Evenamide - Newron Pharmaceuticals
Alternative Names: NW-3509; NW-3509ALatest Information Update: 17 May 2024
At a glance
- Originator Newron Pharmaceuticals
- Class Antidepressants; Antiepileptic drugs; Antimanics; Antipsychotics; Non-opioid analgesics; Small molecules
- Mechanism of Action Dopamine D2 receptor agonists; Dopamine D2 receptor antagonists; Nav1.3 voltage-gated sodium channel inhibitors; NAV1.7 voltage gated sodium channel expression inhibitors; Nav1.7 voltage-gated sodium channel inhibitors; NAV1.8 voltage gated sodium channel expression inhibitors; Nav1.8 voltage-gated sodium channel inhibitors; Serotonin 5-HT2 receptor agonists; Serotonin 5-HT2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Schizophrenia
- Phase II/III Psychiatric disorders
Most Recent Events
- 13 May 2024 Updated efficacy and adverse events data from phase II/III trial in Schizophrenia released by Newron Pharmaceuticals
- 30 Apr 2024 Efficacy and adverse events data from phase II/III trial in Schizophrenia released by Newron Pharmaceuticals
- 04 Jan 2024 Pooled efficacy and adverse event data from phase III 014/015 trial in Schizophrenia released by Newron Pharmaceuticals